Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRUCE C CORSER

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1790727030
CMS profile
171600
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$81,045.88

129 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRUCE C CORSER

NPI 1790727030 · CMS profile ID 171600

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790727030?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRUCE C CORSER, NPI 1790727030, CMS profile ID 171600. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790727030?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BRUCE C CORSER, NPI 1790727030, CMS profile ID 171600. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790727030?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BRUCE C CORSER, NPI 1790727030, CMS profile ID 171600, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1790727030?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

129 matching records · $81,045.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 129 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–129 of 129.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $17.6003/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139299432 CMS
JAZZ PHARMACEUTICALS INC. $21.2003/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232637 CMS
JAZZ PHARMACEUTICALS INC. $218.1203/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232639 CMS
JAZZ PHARMACEUTICALS INC. $5,940.0003/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232575 CMS
JAZZ PHARMACEUTICALS INC. $329.8103/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232573 CMS
JAZZ PHARMACEUTICALS INC. $145.9303/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232571 CMS
JAZZ PHARMACEUTICALS INC. $155.9203/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232537 CMS
JAZZ PHARMACEUTICALS INC. $44.0003/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232539 CMS
JAZZ PHARMACEUTICALS INC. $44.0003/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232567 CMS
JAZZ PHARMACEUTICALS INC. $37.7403/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232611 CMS
JAZZ PHARMACEUTICALS INC. $4,860.0002/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232563 CMS
JAZZ PHARMACEUTICALS INC. $4,860.0002/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232613 CMS
JAZZ PHARMACEUTICALS INC. $5,940.0002/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232633 CMS
JAZZ PHARMACEUTICALS INC. $224.8702/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232535 CMS
JAZZ PHARMACEUTICALS INC. $233.7002/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232565 CMS
JAZZ PHARMACEUTICALS INC. $150.0002/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232569 CMS
JAZZ PHARMACEUTICALS INC. $14.9902/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232533 CMS
JAZZ PHARMACEUTICALS INC. $24.9902/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232543 CMS
JAZZ PHARMACEUTICALS INC. $49.9902/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232553 CMS
JAZZ PHARMACEUTICALS INC. $24.9902/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232555 CMS
JAZZ PHARMACEUTICALS INC. $49.9902/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232605 CMS
JAZZ PHARMACEUTICALS INC. $1,401.2002/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232631 CMS
JAZZ PHARMACEUTICALS INC. $149.9902/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232527 CMS
JAZZ PHARMACEUTICALS INC. $501.7202/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232529 CMS
JAZZ PHARMACEUTICALS INC. $285.3302/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232531 CMS
JAZZ PHARMACEUTICALS INC. $594.7002/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150232541 CMS
IDORSIA PHARMACEUTICALS US INC $13.3001/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146764877 CMS
Axsome Therapeutics, Inc. $26.3101/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148269120 CMS
HARMONY BIOSCIENCES LLC $27.8301/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126068568 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $41,777.53 59
PY2020 $49,012.26 83
PY2021 $92,230.75 120
PY2022 $79,213.13 128
PY2023 $115,989.92 131
PY2024 $81,045.88 129
PY2025 $43,122.04 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $630.62 1
PY2025 Principal investigator $2,294,413.24 490
PY2024 Recipient $60,485.27 2
PY2024 Principal investigator $1,880,775.80 767
PY2023 Principal investigator $1,372,429.52 243
PY2022 Principal investigator $648,950.25 130
PY2021 Principal investigator $1,085,236.29 158
PY2020 Recipient $1,686.03 17
PY2020 Principal investigator $293,284.38 45
PY2019 Principal investigator $125,387.91 122

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

491 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $163,462.10 12/31/2025 Non-covered Recipient Entity
SLEEP MANAGEMENT INSTITUTE INTREPID RESEARCH
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554241
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $120,010.90 12/31/2025 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY DBA STANFORD UNIVERSITY
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554243
Principal investigator 1 Alkermes, Inc. $3,500.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613067
Principal investigator 1 Alkermes, Inc. $3,045.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613697
Principal investigator 1 Alkermes, Inc. $1,750.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615405
Principal investigator 1 Alkermes, Inc. $1,000.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616527
Principal investigator 1 Alkermes, Inc. $2,943.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617535
Principal investigator 1 Alkermes, Inc. $1,450.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619191
Principal investigator 1 Alkermes, Inc. $7,026.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619913
Principal investigator 1 Alkermes, Inc. $800.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622071
Principal investigator 1 Alkermes, Inc. $500.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623442
Principal investigator 1 Alkermes, Inc. $70.00 12/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,310.60 12/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223290016
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60.00 12/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223290018
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $331.80 12/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223289840
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,060.00 12/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223289842
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,761.86 12/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223289868
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,954.40 12/05/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223289262
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,080.00 12/05/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223289314
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,958.00 12/05/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223289316
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,363.00 12/05/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223289318
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 12/05/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223289320
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 12/05/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223289322
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,495.20 12/05/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223289328
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 12/05/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223289330
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $43,202.60 12/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223289156
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,475.20 12/01/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223288951
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,512.00 12/01/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223288953
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,041.85 12/01/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223288999
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.66 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740299
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.42 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740301
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12.48 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740303
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $118.70 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740305
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22.00 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740307
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.99 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740309
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12.83 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740311
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740313
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $74.80 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740315
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740317
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.92 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740319
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.92 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740321
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2.88 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740323
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.66 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740325
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8.12 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740327
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $93.50 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740329
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $119.28 11/24/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740331
Principal investigator 1 Alkermes, Inc. $2,271.00 11/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614587
Principal investigator 1 Alkermes, Inc. $338.00 11/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615601
Principal investigator 1 Alkermes, Inc. $338.00 11/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616695
Principal investigator 1 Alkermes, Inc. $2,271.00 11/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617983
Principal investigator 1 Alkermes, Inc. $810.00 11/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619431
Principal investigator 1 Alkermes, Inc. $810.00 11/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621220
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,102.18 11/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223288537
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,025.08 11/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223288587
Principal investigator 1 Alkermes, Inc. $3,911.00 11/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615229
Principal investigator 1 Alkermes, Inc. $1,337.00 11/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621418
Principal investigator 1 Alkermes, Inc. $70.00 11/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622707
Principal investigator 1 Alkermes, Inc. $2,819.00 11/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623446
Principal investigator 1 Alkermes, Inc. $7,026.00 10/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615225
Principal investigator 1 Alkermes, Inc. $8,383.00 10/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618715
Principal investigator 1 Alkermes, Inc. $2,566.00 10/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618929
Principal investigator 1 Alkermes, Inc. $2,566.00 10/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619909
Principal investigator 1 Alkermes, Inc. $2,487.00 10/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620351
Principal investigator 1 Alkermes, Inc. $7,026.00 10/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623648
Principal investigator 1 Alkermes, Inc. $7,026.00 10/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624941
Principal investigator 1 Alkermes, Inc. $8,383.00 10/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626910
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $196,907.90 10/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223287163
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/15/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223286981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,495.20 10/10/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223286691
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 10/10/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223286693
Principal investigator 1 Alkermes, Inc. $335.00 10/08/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613701
Principal investigator 1 Alkermes, Inc. $801.00 10/08/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615605
Principal investigator 1 Alkermes, Inc. $3,901.00 10/08/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621863
Principal investigator 1 Alkermes, Inc. $1,309.00 10/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615047
Principal investigator 1 Alkermes, Inc. $338.00 10/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620594
Principal investigator 1 Alkermes, Inc. $107.40 10/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613912
Principal investigator 1 Alkermes, Inc. $95.76 10/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617541
Principal investigator 1 Alkermes, Inc. $169.20 10/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618485
Principal investigator 1 Alkermes, Inc. $18.95 10/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619917
Principal investigator 1 Alkermes, Inc. $198.75 10/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625409
Principal investigator 1 Alkermes, Inc. $338.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613377
Principal investigator 1 Alkermes, Inc. $810.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614685
Principal investigator 1 Alkermes, Inc. $338.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615131
Principal investigator 1 Alkermes, Inc. $4,552.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615963
Principal investigator 1 Alkermes, Inc. $2,566.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615965
Principal investigator 1 Alkermes, Inc. $3,696.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616157
Principal investigator 1 Alkermes, Inc. $2,487.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616401
Principal investigator 1 Alkermes, Inc. $6,928.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617635
Principal investigator 1 Alkermes, Inc. $810.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618819
Principal investigator 1 Alkermes, Inc. $810.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619049
Principal investigator 1 Alkermes, Inc. $338.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619537
Principal investigator 1 Alkermes, Inc. $2,487.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619539
Principal investigator 1 Alkermes, Inc. $7,172.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620890
Principal investigator 1 Alkermes, Inc. $8,383.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621112
Principal investigator 1 Alkermes, Inc. $6,928.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621951
Principal investigator 1 Alkermes, Inc. $338.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622395
Principal investigator 1 Alkermes, Inc. $810.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622793
Principal investigator 1 Alkermes, Inc. $2,594.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623048
Principal investigator 1 Alkermes, Inc. $5,905.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623306
Principal investigator 1 Alkermes, Inc. $5,905.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623524
Principal investigator 1 Alkermes, Inc. $5,905.00 09/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624178
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $53.20 09/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223285600
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,549.10 09/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223285339
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $19,876.64 09/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223285379
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $50,656.34 09/10/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740225
Principal investigator 1 Alkermes, Inc. $338.00 09/08/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613171
Principal investigator 1 Alkermes, Inc. $338.00 09/08/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618113
Principal investigator 1 Alkermes, Inc. $1,309.00 09/08/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624873
Principal investigator 1 Alkermes, Inc. $2,481.00 09/08/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626356
Principal investigator 1 Alkermes, Inc. $191.52 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614042
Principal investigator 1 Alkermes, Inc. $9,000.00 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614248
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615311
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616397
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616789
Principal investigator 1 Alkermes, Inc. $132.50 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618599
Principal investigator 1 Alkermes, Inc. $18.80 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618601
Principal investigator 1 Alkermes, Inc. $56.40 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619277
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619281
Principal investigator 1 Alkermes, Inc. $58.23 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620039
Principal investigator 1 Alkermes, Inc. $129.77 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620898
Principal investigator 1 Alkermes, Inc. $52.48 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621312
Principal investigator 1 Alkermes, Inc. $198.75 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622173
Principal investigator 1 Alkermes, Inc. $2,200.00 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622179
Principal investigator 1 Alkermes, Inc. $131.60 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623304
Principal investigator 1 Alkermes, Inc. $75.20 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624859
Principal investigator 1 Alkermes, Inc. $1,000.00 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626152
Principal investigator 1 Alkermes, Inc. $131.60 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626784
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740203
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740205
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740207
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $174.72 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740209
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740211
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $174.72 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740213
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.40 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740215
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740219
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $174.72 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740223
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $159.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740227
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $174.72 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740229
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740231
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.40 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740233
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.40 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740239
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740245
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,118.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740249
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,118.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740251
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740253
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740255
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $174.72 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740259
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $159.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740263
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740265
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740267
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,118.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740269
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $174.72 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740273
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,118.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740275
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740281
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,118.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740283
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,118.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740285
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,118.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740287
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740289
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740291
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,118.60 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740293
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.40 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740295
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $476.01 09/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740297
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $106,060.50 09/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223284927
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,100.00 08/21/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740221
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,250.00 08/21/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740237
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,750.00 08/21/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740257
Principal investigator 1 Alkermes, Inc. $5,905.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613784
Principal investigator 1 Alkermes, Inc. $2,566.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614034
Principal investigator 1 Alkermes, Inc. $7,172.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614691
Principal investigator 1 Alkermes, Inc. $2,566.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614915
Principal investigator 1 Alkermes, Inc. $4,552.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615133
Principal investigator 1 Alkermes, Inc. $5,905.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615969
Principal investigator 1 Alkermes, Inc. $4,552.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616593
Principal investigator 1 Alkermes, Inc. $7,172.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617843
Principal investigator 1 Alkermes, Inc. $2,566.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618105
Principal investigator 1 Alkermes, Inc. $2,594.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618349
Principal investigator 1 Alkermes, Inc. $5,905.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619283
Principal investigator 1 Alkermes, Inc. $7,172.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620033
Principal investigator 1 Alkermes, Inc. $7,172.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620896
Principal investigator 1 Alkermes, Inc. $6,928.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621308
Principal investigator 1 Alkermes, Inc. $2,594.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622795
Principal investigator 1 Alkermes, Inc. $3,696.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623052
Principal investigator 1 Alkermes, Inc. $7,172.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623948
Principal investigator 1 Alkermes, Inc. $2,594.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623950
Principal investigator 1 Alkermes, Inc. $4,552.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624618
Principal investigator 1 Alkermes, Inc. $4,552.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624865
Principal investigator 1 Alkermes, Inc. $2,594.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624869
Principal investigator 1 Alkermes, Inc. $2,271.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625073
Principal investigator 1 Alkermes, Inc. $5,905.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625948
Principal investigator 1 Alkermes, Inc. $4,552.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625952
Principal investigator 1 Alkermes, Inc. $2,487.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625954
Principal investigator 1 Alkermes, Inc. $8,383.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626150
Principal investigator 1 Alkermes, Inc. $5,905.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626788
Principal investigator 1 Alkermes, Inc. $6,928.00 08/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626790
Principal investigator 1 Alkermes, Inc. $70.00 08/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615923
Principal investigator 1 Alkermes, Inc. $2,605.00 08/11/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620243
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,280.16 08/08/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $91,402.50 08/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223283853
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,389.50 08/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223283867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $107,186.80 08/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223283869
Principal investigator 1 Alkermes, Inc. $395.00 08/04/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617245
Principal investigator 1 Alkermes, Inc. $2,508.00 08/04/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208621955
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,743.00 08/01/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223283531
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,080.00 08/01/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223283533
Principal investigator 1 Eli Lilly and Company $210.00 07/31/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187881260
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $22,843.48 07/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283192
Principal investigator 1 Alkermes, Inc. $1,196.53 07/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625227
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,100.00 07/11/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740217
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,500.00 07/11/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740261
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,132.66 07/11/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740277
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,198.70 07/11/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223282556
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,472.00 07/09/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740235
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $212.80 07/09/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740241
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,010.00 07/09/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740243
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,900.00 07/09/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740247
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $52,964.00 07/09/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740271
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $825.00 07/09/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740279
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,299.67 07/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223282484
Principal investigator 1 Alkermes, Inc. $800.00 07/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614919
Principal investigator 1 Alkermes, Inc. $2,180.00 07/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617247
Principal investigator 1 Alkermes, Inc. $969.00 07/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622593
Principal investigator 1 Alkermes, Inc. $395.00 07/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623526
Principal investigator 1 Alkermes, Inc. $395.00 07/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623528
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $291.90 07/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223282380
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,390.00 06/25/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223281882
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613185
Principal investigator 1 Alkermes, Inc. $15.39 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613327
Principal investigator 1 Alkermes, Inc. $91.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613609
Principal investigator 1 Alkermes, Inc. $1,337.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613717
Principal investigator 1 Alkermes, Inc. $12.85 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614062
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614072
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614442
Principal investigator 1 Alkermes, Inc. $70.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614601
Principal investigator 1 Alkermes, Inc. $1.71 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614627
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614747
Principal investigator 1 Alkermes, Inc. $1.75 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614955
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614975
Principal investigator 1 Alkermes, Inc. $8.56 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614981
Principal investigator 1 Alkermes, Inc. $1,540.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614997
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615285
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615507
Principal investigator 1 Alkermes, Inc. $109.20 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615749
Principal investigator 1 Alkermes, Inc. $50.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616219
Principal investigator 1 Alkermes, Inc. $1,337.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616307
Principal investigator 1 Alkermes, Inc. $20.10 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616383
Principal investigator 1 Alkermes, Inc. $29.96 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616467
Principal investigator 1 Alkermes, Inc. $100.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616717
Principal investigator 1 Alkermes, Inc. $128.50 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616823
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617073
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617423
Principal investigator 1 Alkermes, Inc. $8.04 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617433
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617599
Principal investigator 1 Alkermes, Inc. $6.65 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617667
Principal investigator 1 Alkermes, Inc. $15.68 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617833
Principal investigator 1 Alkermes, Inc. $4.90 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617891
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618059
Principal investigator 1 Alkermes, Inc. $2.14 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618403
Principal investigator 1 Alkermes, Inc. $1.96 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618563
Principal investigator 1 Alkermes, Inc. $257.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618639
Principal investigator 1 Alkermes, Inc. $25.68 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618651
Principal investigator 1 Alkermes, Inc. $2.80 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618865
Principal investigator 1 Alkermes, Inc. $0.35 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619103
Principal investigator 1 Alkermes, Inc. $11.76 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619107
Principal investigator 1 Alkermes, Inc. $3,911.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619217
Principal investigator 1 Alkermes, Inc. $9.80 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620285
Principal investigator 1 Alkermes, Inc. $2,819.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622089
Principal investigator 1 Alkermes, Inc. $72.80 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623568
Principal investigator 1 Alkermes, Inc. $37.24 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623582
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623764
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623766
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624220
Principal investigator 1 Alkermes, Inc. $2.10 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625804
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626102
Principal investigator 1 Alkermes, Inc. $72.80 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626202
Principal investigator 1 Alkermes, Inc. $51.40 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626380
Principal investigator 1 Alkermes, Inc. $77.10 06/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626838
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,934.20 06/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223281214
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.70 06/11/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740195
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.72 06/11/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740197
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,473.56 06/11/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223281072
Principal investigator 1 Alkermes, Inc. $9,000.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615253
Principal investigator 1 Alkermes, Inc. $800.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615553
Principal investigator 1 Alkermes, Inc. $2,200.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616761
Principal investigator 1 Alkermes, Inc. $800.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617707
Principal investigator 1 Alkermes, Inc. $395.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619395
Principal investigator 1 Alkermes, Inc. $1,000.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619983
Principal investigator 1 Alkermes, Inc. $7,302.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620766
Principal investigator 1 Alkermes, Inc. $2,117.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622475
Principal investigator 1 Alkermes, Inc. $969.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625141
Principal investigator 1 Alkermes, Inc. $448.00 06/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626418
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613363
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614228
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614230
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615711
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616143
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618593
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619521
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619527
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620011
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620013
Principal investigator 1 Alkermes, Inc. $220.78 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620459
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622381
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623292
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623294
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624160
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624836
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625521
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625744
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626132
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626134
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626138
Principal investigator 1 Alkermes, Inc. $220.78 06/06/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626770
Principal investigator 1 Alkermes, Inc. $64.25 06/04/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613407
Principal investigator 1 Alkermes, Inc. $25.00 06/04/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620504
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $34,582.10 06/04/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223280620
Principal investigator 1 Alkermes, Inc. $395.00 06/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613313
Principal investigator 1 Alkermes, Inc. $7,250.00 06/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619459
Principal investigator 1 Alkermes, Inc. $395.00 06/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622986
Principal investigator 1 Alkermes, Inc. $8,539.00 06/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626308
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,250.00 06/02/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740187
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,492.00 06/02/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740189
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,880.00 06/02/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740191
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,027.00 06/02/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740193
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,750.00 06/02/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740201
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7,300.00 05/23/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740199
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,737.12 05/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223280048
Principal investigator 1 Alkermes, Inc. $1,196.53 05/15/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615267
Principal investigator 1 Alkermes, Inc. $1,196.53 05/15/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620644
Principal investigator 1 Alkermes, Inc. $1,196.53 05/15/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620850
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,956.95 05/14/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223279764
Principal investigator 1 Alkermes, Inc. $784.35 05/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618321
Principal investigator 1 Alkermes, Inc. $784.35 05/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618591
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,488.20 05/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223279380
Principal investigator 1 Alkermes, Inc. $6,216.00 05/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613964
Principal investigator 1 Alkermes, Inc. $2,493.00 05/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614168
Principal investigator 1 Alkermes, Inc. $335.00 05/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615887
Principal investigator 1 Alkermes, Inc. $2,541.00 05/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617777
Principal investigator 1 Alkermes, Inc. $801.00 05/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618017
Principal investigator 1 Alkermes, Inc. $5,713.00 05/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621650
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $36,397.90 04/23/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223278594
Principal investigator 1 Alkermes, Inc. $1,045.00 04/22/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613315
Principal investigator 1 Alkermes, Inc. $8,679.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613281
Principal investigator 1 Alkermes, Inc. $2,319.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613503
Principal investigator 1 Alkermes, Inc. $856.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614158
Principal investigator 1 Alkermes, Inc. $2,605.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614593
Principal investigator 1 Alkermes, Inc. $1,875.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208615871
Principal investigator 1 Alkermes, Inc. $335.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616725
Principal investigator 1 Alkermes, Inc. $335.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617155
Principal investigator 1 Alkermes, Inc. $2,319.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618259
Principal investigator 1 Alkermes, Inc. $335.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618261
Principal investigator 1 Alkermes, Inc. $335.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618735
Principal investigator 1 Alkermes, Inc. $515.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619699
Principal investigator 1 Alkermes, Inc. $3,901.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620363
Principal investigator 1 Alkermes, Inc. $856.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622091
Principal investigator 1 Alkermes, Inc. $801.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622515
Principal investigator 1 Alkermes, Inc. $335.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623198
Principal investigator 1 Alkermes, Inc. $2,317.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623200
Principal investigator 1 Alkermes, Inc. $3,396.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623456
Principal investigator 1 Alkermes, Inc. $2,493.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624088
Principal investigator 1 Alkermes, Inc. $801.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625189
Principal investigator 1 Alkermes, Inc. $335.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625670
Principal investigator 1 Alkermes, Inc. $3,901.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625898
Principal investigator 1 Alkermes, Inc. $2,319.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626696
Principal investigator 1 Alkermes, Inc. $8,500.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626914
Principal investigator 1 Alkermes, Inc. $801.00 04/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208626940
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,961.45 04/18/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223278520
Principal investigator 1 Alkermes, Inc. $1,045.00 04/16/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621668
Principal investigator 1 Alkermes, Inc. $500.00 04/14/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617759
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $194.60 04/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223277772
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 04/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223277774
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 04/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223277776
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $257.15 04/09/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223277778
Principal investigator 1 Alkermes, Inc. $6,265.00 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613868
Principal investigator 1 Alkermes, Inc. $2,340.00 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613870
Principal investigator 1 Alkermes, Inc. $19.75 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615557
Principal investigator 1 Alkermes, Inc. $800.00 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620105
Principal investigator 1 Alkermes, Inc. $4,090.00 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620972
Principal investigator 1 Alkermes, Inc. $800.00 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623132
Principal investigator 1 Alkermes, Inc. $2,794.00 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624915
Principal investigator 1 Alkermes, Inc. $2,221.00 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625860
Principal investigator 1 Alkermes, Inc. $395.00 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626638
Principal investigator 1 Alkermes, Inc. $8,360.00 04/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626640
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,937.28 04/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223277464
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,620.00 04/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223277524
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,725.00 04/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223277526
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,250.00 04/02/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223277528
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,301.20 03/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223276949
Principal investigator 1 Alkermes, Inc. $1,196.53 03/20/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620642
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,600.00 03/14/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) No dispute reported 06/30/2026 1223276743
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,130.00 03/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223276345
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,896.09 03/07/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223276143
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $56,019.42 03/05/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223276051
Principal investigator 1 Alkermes, Inc. $77.64 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614603
Principal investigator 1 Alkermes, Inc. $52.48 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614845
Principal investigator 1 Alkermes, Inc. $228.53 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615633
Principal investigator 1 Alkermes, Inc. $82.08 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616073
Principal investigator 1 Alkermes, Inc. $89.95 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616319
Principal investigator 1 Alkermes, Inc. $113.34 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208617571
Principal investigator 1 Alkermes, Inc. $56.85 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618267
Principal investigator 1 Alkermes, Inc. $228.53 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619705
Principal investigator 1 Alkermes, Inc. $119.36 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619713
Principal investigator 1 Alkermes, Inc. $119.36 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208619945
Principal investigator 1 Alkermes, Inc. $113.34 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622301
Principal investigator 1 Alkermes, Inc. $56.85 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208622739
Principal investigator 1 Alkermes, Inc. $259.54 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623674
Principal investigator 1 Alkermes, Inc. $77.64 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623682
Principal investigator 1 Alkermes, Inc. $82.08 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623864
Principal investigator 1 Alkermes, Inc. $259.54 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624104
Principal investigator 1 Alkermes, Inc. $52.48 03/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626296
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,600.00 02/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) No dispute reported 06/30/2026 1223275489
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,714.34 02/19/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223275409
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208615531
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616475
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616877
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618887
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621380
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621811
Principal investigator 1 Alkermes, Inc. $650.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623386
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208623402
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625609
Principal investigator 1 Alkermes, Inc. $290.00 02/13/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208626226
Principal investigator 1 Alkermes, Inc. $800.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613842
Principal investigator 1 Alkermes, Inc. $25.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614607
Principal investigator 1 Alkermes, Inc. $269.85 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616067
Principal investigator 1 Alkermes, Inc. $395.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616857
Principal investigator 1 Alkermes, Inc. $0.85 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208616957
Principal investigator 1 Alkermes, Inc. $206.20 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617181
Principal investigator 1 Alkermes, Inc. $50.15 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617393
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617779
Principal investigator 1 Alkermes, Inc. $44.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618003
Principal investigator 1 Alkermes, Inc. $44.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618005
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618969
Principal investigator 1 Alkermes, Inc. $2,508.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619351
Principal investigator 1 Alkermes, Inc. $969.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619611
Principal investigator 1 Alkermes, Inc. $25.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620163
Principal investigator 1 Alkermes, Inc. $7.69 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622107
Principal investigator 1 Alkermes, Inc. $448.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208622868
Principal investigator 1 Alkermes, Inc. $89.95 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623186
Principal investigator 1 Alkermes, Inc. $4.80 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623458
Principal investigator 1 Alkermes, Inc. $77.10 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624084
Principal investigator 1 Alkermes, Inc. $11.25 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624764
Principal investigator 1 Alkermes, Inc. $125.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208624969
Principal investigator 1 Alkermes, Inc. $2,180.00 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625125
Principal investigator 1 Alkermes, Inc. $52.80 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625455
Principal investigator 1 Alkermes, Inc. $64.25 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626288
Principal investigator 1 Alkermes, Inc. $12.85 02/12/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626932
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $190.00 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740127
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $102.20 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740129
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,400.00 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740133
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $574.00 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740139
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $271.60 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740141
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,472.00 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740151
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,600.00 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740153
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $91.00 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740155
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $349.44 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740159
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $212.80 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740161
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $176.40 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740163
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,850.00 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740165
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $287.00 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740167
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $349.44 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740173
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,068.80 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740179
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $79.80 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740181
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.80 02/05/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740183
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,492.40 02/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740147
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,492.40 02/03/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740169
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $147,738.92 02/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223274707
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.00 02/02/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740137
Recipient Eli Lilly and Company $630.62 01/31/2025 Covered Recipient Physician A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187876317
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35.00 01/31/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740135
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740143
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $42.00 01/31/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740157
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.00 01/31/2025 Non-covered Recipient Entity
Intrepid Research LLC
An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV No dispute reported 06/30/2026 1233740175
Principal investigator 1 Eli Lilly and Company $65,349.00 01/21/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187884978
Principal investigator 1 Alkermes, Inc. $2,317.00 01/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613227
Principal investigator 1 Alkermes, Inc. $2,317.00 01/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613866
Principal investigator 1 Alkermes, Inc. $856.00 01/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614541
Principal investigator 1 Alkermes, Inc. $335.00 01/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616023
Principal investigator 1 Alkermes, Inc. $5,713.00 01/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620962
Principal investigator 1 Alkermes, Inc. $8,679.00 01/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621564
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $887.60 01/17/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740125
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,253.72 01/17/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740131
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,064.00 01/17/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740145
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,064.00 01/17/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740149
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $887.60 01/17/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740171
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,666.60 01/17/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740177
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,666.60 01/17/2025 Non-covered Recipient Entity
Intrepid Research LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233740185
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,673.65 01/17/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223274239
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,494.62 01/03/2025 Non-covered Recipient Entity
INTREPID RESEARCH LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223273567
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627062
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627136
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
INTREPID RESEARCH, LLC.
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627212